Gout

 

The Rheumatology Network gout clinical focus page provides information on the latest gout news, study and clinical trial findings, and clinical guideline updates. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for gout drugs.

Brad Marder, MD: Pegloticase Therapy in Gout Patients Undergoing Dialysis

April 14, 2021

This week, Rheumatology Network sat down Brad Marder, MD, co-author of the study, Pegloticase Therapy in Gout Patients Undergoing Dialysis: A USRDS Database Study. Data suggests that pegloticase is successful in the treatment of dialysis patients with uncontrolled gout with potentially lower ESA dose requirements after treatment.

Robert Keenan, MD: Efficacy of Combination Therapy for Gout

March 15, 2021

Pegloticase in conjunction with immunomodulator combination therapy significantly increased pegloticase responder rates when compared with pegloticase monotherapy for patients with uncontrolled or refractory gout, according to a study. This week, Rheumatology Network interviewed lead investigator, Robert Keenan, MD, to discuss his findings.

Methotrexate and Pegloticase Combination Therapy Proves to be Effective Gout Treatment

March 12, 2021

Pegloticase (pegylated uricase) is medication approved by the US Food and Drug Administration (FDA) designed to lower sUA in patients with uncontrolled gout. However, 26% of patients have infusion-related reactions (IRs), which may be indicative of the development of antidrug antibodies (ADAs). Due to this, physicians often administer immunomodulators in addition to pegloticase in order to prevent ADAs as well as increase the effectiveness of the therapy.

Initiation of Febuxostat Does Not Prolong Acute Gout Flares

February 26, 2021

“We found that initiation of febuxostat administration during an acute gout flare did not prolong acute flares, and the rate of ‘treat to target’ was higher in the febuxostat group,” investigators concluded. “This may increase patient compliance.”

Reducing the Immunogenicity of Pegloticase in Patients With Refractory Gout

December 21, 2020

Puja Khanna MD, MPH, associate professor of medicine at the University of Michigan, discusses a presentation she gave at the American College of Rheumatology Convergence 2020 on reducing the immunogenicity of pegloticase and improving its efficacy.

Early Trial Shows That Pegloticase Is Safe for Kidney Transplant Patients

October 30, 2020

For kidney transplant patients with gout, the use of anti-inflammatory drugs and urate-lowering therapies typically used to prevent flares and slow the progression disease, are associated with the risk of adverse events. In this interview, Dr. Abdul Abdellatif describes a clinical trial that shows pegloticase may be suitable for transplant patients with gout.

Addressing Misconceptions About Gout

October 29, 2020

In today's episode of the Rheumatology Network podcast Overdrive, we talk with Dr. Bradley Marder, medical director of nephrology for Horizon Therapeutics. Gout, he says, is not only a rheumatic disease that affects peripheral joints, it’s a disease that's systemic in nature and progressive. As a nephrologist, he sees gout as kidney disease. In today's episode of Overdrive, he explains why.

COVID Deaths Are High Among Waitlisted Kidney Transplant Patients

October 29, 2020

Although mortality rates for kidney transplant recipients with COVID-19 are known to be high, end stage kidney disease patients with COVID-19 appear to have a higher risk of mortality than patients with new kidneys.

Kidney Week Wraps With Presentations on COVID and Emerging Therapies

October 27, 2020

From COVID-19 presentations to emerging new therapies for chronic kidney disease, Dr. Bradley Marder, medical director of nephrology with Horizon Therapeutics, offers his take on the most memorable moments from the American Society for Nephrology/Kidney Week annual meeting which wrapped this week.

Allopurinol Doesn’t Slow Kidney Disease

October 23, 2020

The gout treatment allopurinol doesn't appear to slow the progression of chronic kidney disease in patients with moderate to severe loss of kidney function, shows a study presented yesterday at the American Society of Nephrology Kidney Week annual meeting.

Early Results for New Gout Treatments Presented at Kidney Week

October 23, 2020

In today's featured video, we talk with Dr. Brad Marder, medical director at Horizon Therapeutics, who shares with us the details of three studies presented at the American Society of Nephrology annual meeting which is taking place this week online. The studies highlight the preliminary results of clinical trials for new gout treatments. In this interview, he explains why this research is important.

COX-2 Inhibitors Best Traditional NSAIDS for Acute Gout

October 05, 2020

In patients with acute gout, cyclo-oxygenase-2 (COX-2) inhibitors, especially etoricoxib (Arcoxia, Merck & Co.), may result in a greater clinical response than traditional non-steroidal anti-inflammatory drugs (NSAIDs), according to a study published in BMJ Open.

Dapagliflozin Earns Breakthrough Therapy Designation for Chronic Kidney Disease

October 02, 2020

Dapagliflozin (Farxiga, AstraZeneca) has been granted breakthrough therapy designation by the U.S. Food and Drug Administration for patients with chronic kidney disease with and without type 2 diabetes. It is currently approved as a treatment to improve glycemic control in adults with type 2 diabetes.

Gout As Kidney Disease

October 02, 2020

Gout is not only an intermittent disease that affects peripheral joints, it’s a disease that's systemic in nature and progressive, says Dr. Bradley Marder, medical director of nephrology with Horizon Therapeutics. As a nephrologist, he sees gout as a kidney disease. In this interview, he explains why.

Adopting Right-Sized Patient Care in Rheumatology

August 28, 2020

In this week's one-on-one interview, we talk with Dr. Jeffrey Curtis of the University of Alabama. We spoke about the use of activity trackers as a tool to record and track arthritic flare-ups. The device has been found to be useful in improving patient care or as Dr. Curtis says, “we need to right-size care” by giving patients the right care at the right time.” In this interview, he explains how an activity tracker can make such a huge difference in the care patients receive.

Studies Link Gout Flares to Consuming Sodas

August 25, 2020

A systematic review and meta-analysis recently published the Journal of Human Nutrition and Dietetics finds that consuming sugar-sweetened beverages is significantly associated with increased serum uric acid concentrations associated with gout flares.

Talking Gout and Myths with Dr. Christopher Parker

May 29, 2020

In this week's news roundup from Rheumatology Network we continue our series on gout. Last week we featured a discussion with Dr. John D. Fitzgerald focusing on ACR's new gout treatment guidelines and this week, we talk with Dr. Christopher Parker, chief of rheumatology at Austin Diagnostic Clinic in Texas. Dr. Parker addresses mythbusters and patient engagement.